{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:33Z","timestamp":1790996193359,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.01.013","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:00:55Z","timestamp":1770134455000},"page":"e603-e610.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"Klaus Martin","family":"Kort\u00fcm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0684-1510","authenticated-orcid":false,"given":"James","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cislo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-7534","authenticated-orcid":false,"given":"Jaime","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-1374","authenticated-orcid":false,"given":"Moritz","family":"Lehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-9049","authenticated-orcid":false,"given":"Keltie","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"R\u00fcckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6320-4324","authenticated-orcid":false,"given":"Kai","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-8258","authenticated-orcid":false,"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2026.01.013_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"10272","key":"10.1016\/j.clml.2026.01.013_bib0002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2026.01.013_bib0003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.01.013_bib0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2026.01.013_sbref0005","series-title":"Multiple Myeloma","year":"2023"},{"issue":"5","key":"10.1016\/j.clml.2026.01.013_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.clml.2026.01.013_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2026.01.013_bib0008","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jha2.743","article-title":"Difficult-to-treat patients with relapsed\/refractory multiple myeloma: a review of clinical trial results","volume":"4","author":"Raab","year":"2023","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.clml.2026.01.013_bib0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-021-01109-y","article-title":"Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond","volume":"14","author":"Su","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.01.013_bib0010","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Elranatamab (multiple myeloma, at least 3 prior therapies. 2024. Available at: https:\/\/www.g-ba.de\/beschluesse\/6699\/. Accessed January 21, 2026."},{"key":"10.1016\/j.clml.2026.01.013_bib0011","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Teclistamab (multiple myeloma, at least 3 prior therapies). 2024. Available at: https:\/\/www.g-ba.de\/beschluesse\/6497\/. Accessed January 21, 2026."},{"key":"10.1016\/j.clml.2026.01.013_bib0012","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Talquetamab (multiple myeloma, at least 3 prior therapies). 2025. Available at: https:\/\/www.g-ba.de\/beschluesse\/7167\/. Accessed January 21, 2026."},{"key":"10.1016\/j.clml.2026.01.013_bib0013","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies). 2024. Available at: https:\/\/www.g-ba.de\/beschluesse\/6967\/. Accessed January 21, 2026."},{"key":"10.1016\/j.clml.2026.01.013_bib0014","unstructured":"Gemeinsamer Bundesausschuss (G-BA). Ciltacabtagene autoleucel (multiple myeloma, after at least 1 prior therapy, refractory to lenalidomide). 2025. Available at: https:\/\/www.g-ba.de\/beschluesse\/7209\/. Accessed January 21, 2026."},{"key":"10.1016\/j.clml.2026.01.013_bib0015","series-title":"StatPearls","article-title":"Relapsed and refractory multiple myeloma","author":"Ahmed","year":"2025"},{"issue":"1","key":"10.1016\/j.clml.2026.01.013_bib0016","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.01.013_bib0017","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.clml.2026.01.013_bib0018","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.01.013_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41408-024-01120-9","article-title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","volume":"14","author":"Joseph","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2026.01.013_bib0020","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.01.013_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235996","article-title":"Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, imid and Anti-CD-38 from a German registry","volume":"13","author":"Merz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2026.01.013_bib0022","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1182\/blood-2019-128030","article-title":"Treatment patterns in patients (pts) with refractory\/relapsed multiple myeloma (RRMM) in Germany between 2016 and 2018","volume":"134","author":"Merz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.013_bib0023","series-title":"StatPearls","article-title":"Relapsed and refractory multiple myeloma","author":"Ahmed","year":"2023"},{"key":"10.1016\/j.clml.2026.01.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107677","article-title":"Outcomes of triple-class refractory multiple myeloma patients at a single clinic: a retrospective study","volume":"151","author":"Danis","year":"2025","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2026.01.013_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-025-01711-4","article-title":"Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting","volume":"18","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.clml.2026.01.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115157","article-title":"Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials","volume":"215","author":"Yong","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.01.013_bib0027","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","article-title":"Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide","volume":"9","author":"Moreau","year":"2019","journal-title":"Blood Cancer J"},{"issue":"S3","key":"10.1016\/j.clml.2026.01.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970680.25812.6d","article-title":"P944: real-world patient characteristics and survival outcomes of lenalidomide refractory vs. lenalidomide exposed rrmm patients in the Honeur Federated Data Network","volume":"7","author":"Spicka","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.01.013_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.01.013_bib0030","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.clml.2026.01.013_bib0031","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.2011.822","article-title":"Surveillance bias in outcomes reporting","volume":"305","author":"Haut","year":"2011","journal-title":"JAMA"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:37:56Z","timestamp":1778067476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000285"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An oBservational retrospective Analysis of treatment patternS and Effectiveness of standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor: BasecaMMp Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}